The specific treatment strategy for secondary hyperparathyroidism varies depending on the primary disease, and the current clinical treatment options include drug therapy and surgery. 1. Drug therapy: For hyperparathyroidism secondary to chronic kidney disease, patients need to supplement active vitamin D or its analogs to inhibit the synthesis and secretion of parathyroid hormone because the ability of renal active vitamin D synthesis decreases. Commonly used drugs include osteotriol and paricalcitol. For patients suffering from vitamin D deficiency or insufficiency, increased sunlight exposure is recommended, along with administration of common vitamin D preparations. For patients with renal 1α hydroxylase deficiency, vitamin D preparations that do not require 1α hydroxylation should be chosen, including osteotriol and alfacalcitol. For patients with vitamin D receptor resistance, large doses of vitamin D preparations are usually needed, and blood and urine calcium and phosphorus levels need to be monitored during treatment. 2. Surgery: Parathyroidectomy is mainly for patients with refractory hyperparathyroidism, which can effectively reduce parathyroid hormone, improve calcium and phosphorus metabolism, and improve the quality of patient’s survival. It can effectively relieve symptoms such as bone pain, muscle weakness and itching, reduce the risk of bone fracture, and improve the abnormality of serum biochemical indexes. The three commonly used surgical procedures include total parathyroidectomy, complete parathyroidectomy with autologous forearm transplantation, and subtotal parathyroidectomy. Patients are advised to go to regular hospitals for treatment according to their symptoms in order to avoid delaying the disease and causing serious consequences.